Israel China Biotechnology (ICB) Ltd (ICB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Israel China Biotechnology (ICB) Ltd (ICB) has a cash flow conversion efficiency ratio of -0.415x as of June 2021. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.06 Million ≈ $-2.84K USD) by net assets (ILA2.55 Million ≈ $6.83K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Israel China Biotechnology (ICB) Ltd to measure how much of total assets are equity-financed.
Israel China Biotechnology (ICB) Ltd - Cash Flow Conversion Efficiency Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Israel China Biotechnology (ICB) Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Israel China Biotechnology (ICB) Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Israel China Biotechnology (ICB) Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Premium Catering (Holdings) Limited
NASDAQ:PC
|
N/A |
|
Mountain Alliance AG
XETRA:ECF
|
-0.021x |
|
Outback Goldfields Corp
V:OZ
|
-0.040x |
|
Plastofil -L
TA:PPIL
|
0.006x |
|
Penpower Technology Ltd
TWO:5211
|
-0.016x |
|
Eagon Ind
KO:008250
|
0.033x |
|
Tandy Leather Factory Inc
NASDAQ:TLF
|
0.019x |
|
Gensight Biologics SA
PA:SIGHT
|
0.260x |
Annual Cash Flow Conversion Efficiency for Israel China Biotechnology (ICB) Ltd (2015–2020)
The table below shows the annual cash flow conversion efficiency of Israel China Biotechnology (ICB) Ltd from 2015 to 2020. For the full company profile with market capitalisation and key ratios, see Israel China Biotechnology (ICB) Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2020-12-31 | ILA470.00K ≈ $1.26K |
ILA-4.34 Million ≈ $-11.63K |
-9.232x | -312.74% |
| 2019-12-31 | ILA1.89 Million ≈ $5.06K |
ILA-4.22 Million ≈ $-11.32K |
-2.237x | -248.93% |
| 2018-12-31 | ILA7.41 Million ≈ $19.87K |
ILA-4.75 Million ≈ $-12.74K |
-0.641x | -134.10% |
| 2017-12-31 | ILA-1.69 Million ≈ $-4.52K |
ILA-3.17 Million ≈ $-8.50K |
1.880x | +190.81% |
| 2016-12-31 | ILA1.91 Million ≈ $5.11K |
ILA-3.94 Million ≈ $-10.58K |
-2.070x | -213.83% |
| 2015-12-31 | ILA5.78 Million ≈ $15.50K |
ILA-3.81 Million ≈ $-10.23K |
-0.660x | -- |
About Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.